United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 3

Name: Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 3 comparison snapshot
Creator: Fliar BI Prism

A five-company surgical and medical instruments and apparatus cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderBecton Dickinson · 50

Strongest available pathGlaukos · +266.8%

Widest latest marginGlobus Medical · 18.3%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1BDX · NYSE

Becton Dickinson

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1897Franklin Lakes$50.97B market cap

View full Companies Radar profile

50Moderate

Snapshot price$187.1as of page date

Monthly-close return-0.8%five-year window

FY2025 revenue$21.84BBECTON DICKINSON & CO

Net margin7.7%FY2025

P/E snapshot32.4xone ratio, not a verdict

Prism attention57.3%share across these five

Filing track recordRevenue, USD billions

+7.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.9%

52-week position91% through range

$127.6$193.1

News mentions7.2K

Community mentions225partial coverage

U.S.-scope patents25013

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal77/100
Management stability90/100
Market position33/100
Capital-event signal24/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 26 M&A involvements, 11 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2GMED · NYSE

Globus Medical

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2003WILMINGTON$10.81B market cap

View full Companies Radar profile

50Moderate

Snapshot price$80.48as of page date

Monthly-close return+5.0%five-year window

FY2025 revenue$2.94BGLOBUS MEDICAL INC

Net margin18.3%FY2025

P/E snapshot20.6xone ratio, not a verdict

Prism attention20.9%share across these five

Filing track recordRevenue, USD billions

+206.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 32.3%

52-week position56% through range

$54.15$101.4

News mentions2.6K

Community mentions61partial coverage

U.S.-scope patents5179

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal77/100
Management stability90/100
Market position23/100
Capital-event signal20/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 21 M&A involvements, 5 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3DRIO · Nasdaq

DarioHealth

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2011New York City$68.8M market cap

View full Companies Radar profile

49Cautious

Snapshot price$7.02as of page date

Monthly-close return-97.4%five-year window

FY2025 revenue$0.02BDarioHealth Corp.

Net margin-186.6%FY2025

P/E snapshot-6.3xone ratio, not a verdict

Prism attention7.5%share across these five

Filing track recordRevenue, USD billions

+9.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.2%

52-week position10% through range

$5.84$17.74

News mentions939

Community mentions0partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal32/100
Management stability90/100
Market position23/100
Capital-event signal81/100
Innovation pulse27/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 10 M&A involvements, 2 asset-acquisition events and 34 contract events.

Innovation activity

Prism records 6 lifetime product-launch events, 1 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4GKOS · NYSE

Glaukos

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2001Laguna Hills, California$10.42B market cap

View full Companies Radar profile

49Cautious

Snapshot price$176.7as of page date

Monthly-close return+266.8%five-year window

FY2025 revenue$0.51BGLAUKOS Corp

Net margin-37.0%FY2025

P/E snapshot350.4xone ratio, not a verdict

Prism attention11.1%share across these five

Filing track recordRevenue, USD billions

+72.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 14.6%

52-week position87% through range

$73.16$191.6

News mentions1.4K

Community mentions11partial coverage

U.S.-scope patents486

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal82/100
Management stability90/100
Market position8/100
Capital-event signal30/100
Innovation pulse3/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5NEPH · Nasdaq

Nephros

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1997River Edge, New Jersey$44.5M market cap

View full Companies Radar profile

49Cautious

Snapshot price$4.10as of page date

Monthly-close return-53.2%five-year window

FY2025 revenue$0.02BNEPHROS INC

Net margin6.4%FY2025

P/E snapshot25.6xone ratio, not a verdict

Prism attention3.2%share across these five

Filing track recordRevenue, USD billions

+81.8%

FY2019–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 16.1%

52-week position38% through range

$2.66$6.42

News mentions400

Community mentions0partial coverage

U.S.-scope patents163

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal62/100
Management stability90/100
Market position6/100
Capital-event signal67/100
Innovation pulse7/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 3 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Glaukos

+266.8%

Globus Medical

+5.0%

Becton Dickinson

-0.8%

Nephros

-53.2%

DarioHealth

-97.4%

Latest revenue

USD billions, official filing scope shown on each company card.

Becton Dickinson

$21.84B

Globus Medical

$2.94B

Glaukos

$0.51B

DarioHealth

$0.02B

Nephros

$0.02B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Globus Medical

18.3%

Becton Dickinson

7.7%

Nephros

6.4%

Glaukos

-37.0%

DarioHealth

-186.6%

Prism news attention

Normalized share across these five names; attention is not quality.

Becton Dickinson

57.3%

Globus Medical

20.9%

Glaukos

11.1%

DarioHealth

7.5%

Nephros

3.2%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Becton Dickinson leads the conversation

It holds 57.3% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $21.84B.

Price path

Glaukos leads the available price paths

Its monthly-close return is +266.8% for the five-year window. At the other end, DarioHealth is -97.4% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Globus Medical has the widest latest margin

Its FY2025 net margin is 18.3%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

DarioHealth shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -6.3x while its five-year window price return is -97.4%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · BDX

Becton Dickinson

7,210available Prism news records

Prism top themes

Price action & investor response

174

Capital allocation & transactions

131

Leadership & governance

Earnings & financial performance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-1.4%937 latest 12m vs 950 prior 12m

Machine-classified coverage tone

92.5% positive+3.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 37stock price 32investment deal 23stem cell banking 23stock surge 21cell-based therapies 18device-biologic combination 17antimicrobial resistance surveillance 16

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-13 · trend and themes shown through 2026-06

Areas of research · GMED

Globus Medical

2,631available Prism news records

Prism top themes

Earnings & financial performance

117

Price action & investor response

Leadership & governance

Legal, arbitration & regulatory

Macro demand & rates

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-14.1%401 latest 12m vs 467 prior 12m

Machine-classified coverage tone

91.8% positive+7.4 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

earnings report 35quarterly results 28annual earnings 26financial report 24profit statement 22quarterly financials 21stock performance 20robotic surgery 20

Keyword tag occurrences in available Prism news records.

Coverage: 2010-03-16–2026-06-19 · trend and themes shown through 2026-06

Areas of research · DRIO

DarioHealth

939available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-28.6%75 latest 12m vs 105 prior 12m

Machine-classified coverage tone

89.4% positive-5.3 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 9stock performance 9digital health consultation 8earnings report 8preventive health initiative 7lifestyle medicine 6investor conference 5pharma digital strategy 4

Keyword tag occurrences in available Prism news records.

Coverage: 2015-12-31–2026-05-16 · trend and themes shown through 2026-05

Areas of research · GKOS

Glaukos

1,397available Prism news records

Prism top themes

Price action & investor response

110

Earnings & financial performance

Capital allocation & transactions

Macro demand & rates

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+44.1%330 latest 12m vs 229 prior 12m

Machine-classified coverage tone

92.7% positive+2.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 41stock performance 31share price 28stock surge 25investment deal 16market reaction 13market response 11stock indices 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-10 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

BDX

Becton Dickinson

225 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 225 records remained after filtering.

GMED

Globus Medical

61 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 61 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

BDX

Becton Dickinson

through 2026-03-20

Earnings releases 10M&A 10Asset acquisitions 4Company announcements 2Lawsuits 2

2026-03-20
Asset acquisitions
Waters completed its $18.8 billion buy of Becton Dickinson’s biosciences and diagnostics business last month.
2026-02-11
Earnings releases
Based on Becton Dickinson’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.25 billion and a net profit of $382 million.
2026-02-09
Business contracts
Waters on Wednesday announced the completion of its $18.8 billion deal to combine with Becton Dickinson's Biosciences & Diagnostic Solutions business.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

GMED

Globus Medical

through 2026-02-26

Earnings releases 42M&A 11Leadership changes 7Asset acquisitions 1

2026-02-26
Earnings releases
Company Earnings Amt % of Sales Sales $826.4 Cost of Sales $261.1 31.6% R & D $36.1 4.4% Selling and Admin $318.5 38.5% Other $70.1 8.5% Net Earnings $140.6 17%
2025-07-21
Leadership changes
Daniel Scavilla has resigned as President and Chief Executive Officer to pursue another opportunity as President and CEO of Dentsply Sirona.
2025-04-03
M&A
Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

DRIO

DarioHealth

through 2026-05-04

Earnings releases 32Business contracts 9Leadership changes 8M&A 5Company announcements 1

2026-05-04
Earnings releases
DarioHealth Corp. announced today that it will release its financial results for the 1st quarter ended March 31 st , 2026
2026-04-13
Leadership changes
today announced the appointment of John R. Palumbo to its Board of Directors.
2026-03-30
Business contracts
We entered into sales agreement, dated March 30, 2026 (the “Sales Agreement”), with A.G.P./Alliance Global Partners (“A.G.P.” or the “Agent”), relating to shares of our common stock.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

GKOS

Glaukos

through 2026-04-30

Earnings releases 28Company announcements 3M&A 2Lawsuits 1Regulatory 1

2026-04-30
Earnings releases
The company reported net sales of $150.6 million for the quarter ended March 31, a 41% increase from the year-ago period on a reported basis and 39% on a constant-currency basis.
2026-04-17
Company announcements
EYECARE Glaukos Releases Its 2025 Sustainability Report, Highlighting Key Milestones Staff By ALISO VIEJO, Calif.—
2025-02-14
M&A
President and CEO Tom Burns noted that the deal values Waltham, Mass.-based Avedro at about $26.68 per share, for a total value of about $500 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NEPH

Nephros

through 2026-04-16

Earnings releases 23Leadership changes 8Company announcements 3Asset acquisitions 1

2026-04-16
Leadership changes
Nephros Inc., a water technology company providing filtration solutions to medical and commercial markets, announced an expansion of its strategic focus in the Greater New York City region with the addition of Dana Cunningham as a dedicated regional sales leader.
2026-03-12
Earnings releases
The company achieved net income of $1.2 million for the year, representing its second consecutive year of positive net income.
2026-02-13
Company announcements
Nephros Inc., a water technology company providing filtration solutions to medical and commercial markets, announced its entry into the Puerto Rican market on February 13, 2026.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence

2019 extracted base$10.20B–$11.75B

2025 extracted forecast$11.50B–$21.52B

Implied source CAGR7.4%

increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records

Latest 12m volume+8.7%36648 vs 33721 records

Positive classified tone66.7%+5.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

7,802

medical drama series

7,076

cannabis legalization trends & economic impact

6,207

recreational marijuana usage

5,579

in-flight medical emergency protocols

4,688

medical marijuana laws & regulatory frameworks

3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 11–18. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Becton Dickinson leads the readiness ranking

Its Prism readiness score is 50/100, the highest in this five-company comparison.

Open Becton Dickinson in Companies Radar

Scale and margin leadership sit with Becton Dickinson and Globus Medical

Becton Dickinson has the largest displayed latest revenue at $21.84B; Globus Medical has the widest displayed latest margin at 18.3%.

Open Becton Dickinson in Companies Radar Open Globus Medical in Companies Radar

Comparisons

Strongest versus weakest available price path

Glaukos is +266.8% for its five-year window; DarioHealth is -97.4% for its five-year window.

Open Glaukos in Companies Radar Open DarioHealth in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $21.84B for Becton Dickinson to $0.02B for Nephros. Entity and filing-period labels remain visible on the company cards.

Open Becton Dickinson in Companies Radar Open Nephros in Companies Radar

Anomalies

Glaukos has the widest attention-readiness rank gap

It ranks #3 by measured news attention (11.1%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Glaukos in Companies Radar

Nephros shows a price-operating divergence to inspect

Its displayed filing-revenue change is +81.8% while its available monthly-close return is -53.2%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Nephros in Companies Radar

Explanations

Attention measures coverage volume, not quality

Becton Dickinson's 57.3% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Becton Dickinson in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Becton Dickinson's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 50/100 score.

Open Becton Dickinson in Companies Radar

Stress-test the largest divergence before forming a view

Compare Nephros's profile with Glaukos's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Nephros in Companies Radar Open Glaukos in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.